AMBUJACEM Stock Overview
Manufactures and markets cement and cement related products to individual homebuilders, masons and contractors, and architects and engineers in India.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 1/6 |
| Past Performance | 5/6 |
| Financial Health | 5/6 |
| Dividends | 3/6 |
Ambuja Cements Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹631.80 |
| 52 Week High | ₹706.95 |
| 52 Week Low | ₹404.05 |
| Beta | 0.17 |
| 11 Month Change | -8.61% |
| 3 Month Change | -0.55% |
| 1 Year Change | 40.73% |
| 33 Year Change | 58.60% |
| 5 Year Change | 215.82% |
| Change since IPO | 1,483.19% |
Recent News & Updates
Recent updates
Here's Why Ambuja Cements (NSE:AMBUJACEM) Can Manage Its Debt Responsibly
Jul 23
Returns On Capital At Ambuja Cements (NSE:AMBUJACEM) Have Stalled
May 30Ambuja Cements' (NSE:AMBUJACEM) Promising Earnings May Rest On Soft Foundations
May 09There's Reason For Concern Over Ambuja Cements Limited's (NSE:AMBUJACEM) Price
Apr 22Ambuja Cements (NSE:AMBUJACEM) Hasn't Managed To Accelerate Its Returns
Feb 01Is Ambuja Cements (NSE:AMBUJACEM) A Risky Investment?
Dec 21Ambuja Cements (NSE:AMBUJACEM) Could Be Struggling To Allocate Capital
Oct 18Is Ambuja Cements (NSE:AMBUJACEM) A Risky Investment?
Sep 22Returns On Capital At Ambuja Cements (NSE:AMBUJACEM) Paint A Concerning Picture
Jul 09Is Ambuja Cements (NSE:AMBUJACEM) Using Too Much Debt?
Jun 18Ambuja Cements (NSE:AMBUJACEM) Will Want To Turn Around Its Return Trends
Mar 26Is Ambuja Cements (NSE:AMBUJACEM) Using Too Much Debt?
Mar 08Weak Statutory Earnings May Not Tell The Whole Story For Ambuja Cements (NSE:AMBUJACEM)
Feb 15Ambuja Cements' (NSE:AMBUJACEM) Shareholders Will Receive A Bigger Dividend Than Last Year
Mar 27We Like These Underlying Return On Capital Trends At Ambuja Cements (NSE:AMBUJACEM)
Mar 25Is Ambuja Cements (NSE:AMBUJACEM) Using Too Much Debt?
Mar 08Ambuja Cements' (NSE:AMBUJACEM) Dividend Will Be Increased To ₹6.30
Feb 23Shareholder Returns
| AMBUJACEM | IN Basic Materials | IN Market | |
|---|---|---|---|
| 7D | 1.4% | 4.3% | 3.7% |
| 1Y | 40.7% | 30.9% | 44.9% |
Return vs Industry: AMBUJACEM exceeded the Indian Basic Materials industry which returned 29.3% over the past year.
Return vs Market: AMBUJACEM underperformed the Indian Market which returned 44.3% over the past year.
Price Volatility
| AMBUJACEM volatility | |
|---|---|
| AMBUJACEM Average Weekly Movement | 6.5% |
| Basic Materials Industry Average Movement | 5.8% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in IN Market | 9.8% |
| 10% least volatile stocks in IN Market | 4.4% |
Stable Share Price: AMBUJACEM has not had significant price volatility in the past 3 months.
Volatility Over Time: AMBUJACEM's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1981 | 3,548 | Ajay Kapur | www.ambujacement.com |
Ambuja Cements Limited, together with its subsidiaries, manufactures and markets cement and cement related products to individual homebuilders, masons and contractors, and architects and engineers in India. The company offers Portland pozzolana cement and ordinary Portland cement, as well as temperature resistant concrete blocks, Blaine Portland cement, and micro materials. It sells its products through dealers, authorized retail stockiest, retailers, and authorized sales representatives.
Ambuja Cements Limited Fundamentals Summary
| AMBUJACEM fundamental statistics | |
|---|---|
| Market cap | ₹1.56t |
| Earnings (TTM) | ₹33.17b |
| Revenue (TTM) | ₹327.58b |
47.0x
P/E Ratio4.8x
P/S RatioIs AMBUJACEM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AMBUJACEM income statement (TTM) | |
|---|---|
| Revenue | ₹327.58b |
| Cost of Revenue | ₹134.66b |
| Gross Profit | ₹192.92b |
| Other Expenses | ₹159.75b |
| Earnings | ₹33.17b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Oct 28, 2024
| Earnings per share (EPS) | 13.47 |
| Gross Margin | 58.89% |
| Net Profit Margin | 10.13% |
| Debt/Equity Ratio | 1.4% |
How did AMBUJACEM perform over the long term?
See historical performance and comparison